Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the preclinical and early clinical activity and side effects of docetaxel, showing its significant effectiveness against various cancers with neutropenia as a major side effect.

This study found that the combination of docetaxel, cisplatin, and 5-fluorouracil is active and feasible for treating squamous cell carcinoma of the head and neck, with dose level I recommended for further testing.

This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.

Scalp cooling significantly reduces hair loss in chemotherapy patients.

This study found that long-term weekly administration of docetaxel is feasible at doses up to 45 mg/m² per week with acceptable toxicity, and suggests further evaluation with 40 mg/m² for phase II studies.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

In this study, in vitro and in vivo models showed that chrysin enhanced the efficacy of docetaxel and reduced its adverse effects in non–small cell lung cancer treatment.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.

In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This study suggests that compounds from turmeric and bitter have potential antiviral activity against the influenza A virus by inhibiting the polymerase PA-PB1, warranting further experimental verification.

In this study, EC chemotherapy was found to be noninferior to TC in causing grade 3 or 4 neutropenia among HR+/HER2-negative breast cancer patients, but EC was associated with more other adverse events.

This study found that higher levels of DHA from omega-3 fatty acids delayed inflammation resolution and impaired wound healing quality in both transgenic mice and wild-type mice supplemented with DHA.

This correspondence comments on the unknown prevalence of permanent alopecia following high-dose docetaxel chemotherapy and highlights the need for further understanding and prevention strategies.

This study found that paclitaxel poliglumex induces significantly less and milder alopecia compared with standard taxanes in ovarian and breast cancer patients.

This study found that the epirubicin-docetaxel chemotherapy regimen for metastatic breast cancer resulted in a clinical response in 55% of patients, with maintained global quality of life despite some impairments.

In this study, wearing a frozen glove during docetaxel chemotherapy reduced nail problems in patients' gloved hands compared to unprotected hands, with onycholysis absent among protected hands.

This article discusses the role of dermal papilla and dermal sheath cells in the hair cycle and reviews finasteride and minoxidil's mechanisms in promoting hair growth, but presents no new clinical findings.

Health experts should not ignore their own health issues and seeking treatment is important for their well-being and work.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

This article highlights variability in graft estimates for hair transplants across different doctors and suggests it reflects poorly on the hair restoration field, without providing specific new data.

This research examined krill oil's effects on benign prostatic hyperplasia and found that it inhibited the growth of prostate cells in vitro and reduced prostate size and weight in a BPH rat model, suggesting potential as a prophylactic or therapeutic agent for BPH.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

This review discusses the common occurrence of docetaxel-induced hair loss in cancer patients, including permanent cases, and highlights current and experimental strategies like scalp cooling, minoxidil, and new clinical trials for managing and preventing this side effect.

In this consensus document, 34 dermatologists from the Spanish Trichology Society used the Delphi method to create comprehensive recommendations for managing androgenetic alopecia, offering guidance based on expert opinion and available scientific evidence to assist clinicians in routine treatment.

This study reported that dupilumab successfully induced remission of chronic, disseminated eczema herpeticum in a six-year-old girl with DOCK8-deficiency hyper-IgE syndrome, achieving complete resolution of herpetic lesions and significant skin, hair, and nail improvement within three months.

This study investigated the effects of HDDPiW-jSB solution on chemotherapy-induced alopecia in a rat model and found that the solution improved hair follicle health markers and reduced cell apoptosis, especially when applied twice weekly, while appearing safe for skin application.

This paper reviews delusional infestation, its characteristics, and treatment options, highlighting a case study of a man with a strong belief in a nonexistent lice infestation and recommending low-dose antipsychotics for primary cases.

This article reviews clinical issues and dermatologist perspectives on managing periungual lesions in patients undergoing docetaxel chemotherapy, but it reports no new clinical outcomes.